Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2005 2
2007 1
2009 3
2010 4
2013 2
2016 1
2018 2
2019 1
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Diagnostic markers of urothelial cancer based on DNA methylation analysis.
Chihara Y, Kanai Y, Fujimoto H, Sugano K, Kawashima K, Liang G, Jones PA, Fujimoto K, Kuniyasu H, Hirao Y. Chihara Y, et al. Among authors: kawashima k. BMC Cancer. 2013 Jun 4;13:275. doi: 10.1186/1471-2407-13-275. BMC Cancer. 2013. PMID: 23735005 Free PMC article.
Salvage Radiotherapy Versus Hormone Therapy for Prostate-specific Antigen Failure After Radical Prostatectomy: A Randomised, Multicentre, Open-label, Phase 3 Trial (JCOG0401)†.
Yokomizo A, Wakabayashi M, Satoh T, Hashine K, Inoue T, Fujimoto K, Egawa S, Habuchi T, Kawashima K, Ishizuka O, Shinohara N, Sugimoto M, Yoshino Y, Nihei K, Fukuda H, Tobisu KI, Kakehi Y, Naito S; JCOG0401 Investigators. Yokomizo A, et al. Among authors: kawashima k. Eur Urol. 2020 Jun;77(6):689-698. doi: 10.1016/j.eururo.2019.11.023. Epub 2019 Dec 19. Eur Urol. 2020. PMID: 31866092 Clinical Trial.
Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS): first analysis on survival.
Ito K, Saito S, Yorozu A, Kojima S, Kikuchi T, Higashide S, Aoki M, Koga H, Satoh T, Ohashi T, Nakamura K, Katayama N, Tanaka N, Nakano M, Shigematsu N, Dokiya T, Fukushima M; J-POPS Investigators. Ito K, et al. Int J Clin Oncol. 2018 Dec;23(6):1148-1159. doi: 10.1007/s10147-018-1309-0. Epub 2018 Jun 22. Int J Clin Oncol. 2018. PMID: 29934842
Curative surgery for local pelvic recurrence of rectal cancer.
Saito N, Koda K, Takiguchi N, Oda K, Ono M, Sugito M, Kawashima K, Ito M. Saito N, et al. Among authors: kawashima k. Dig Surg. 2003;20(3):192-9; discussion 200. doi: 10.1159/000070385. Dig Surg. 2003. PMID: 12759498
Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer.
Miyake M, Sugano K, Sugino H, Imai K, Matsumoto E, Maeda K, Fukuzono S, Ichikawa H, Kawashima K, Hirabayashi K, Kodama T, Fujimoto H, Kakizoe T, Kanai Y, Fujimoto K, Hirao Y. Miyake M, et al. Among authors: kawashima k. Cancer Sci. 2010 Jan;101(1):250-8. doi: 10.1111/j.1349-7006.2009.01334.x. Epub 2009 Sep 1. Cancer Sci. 2010. PMID: 19843069 Free article.
1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest.
Miyake M, Ishii M, Koyama N, Kawashima K, Kodama T, Anai S, Fujimoto K, Hirao Y, Sugano K. Miyake M, et al. Among authors: kawashima k. J Pharmacol Exp Ther. 2010 Mar;332(3):795-802. doi: 10.1124/jpet.109.162768. Epub 2009 Dec 2. J Pharmacol Exp Ther. 2010. PMID: 19955487
16 results